In mice, subcutaneous injection of a CCR2 inhibitor (PF-04136309) ablated inflammatory monocytes and macrophages not only in the primary tumor but also in the pre-metastatic niche, leading to decreased tumor growth and metastases, as well as improved anti-tumor immunity [64]. The gene discussed is CCR2; the disease is neoplasm.